Results 71 to 80 of about 2,912 (169)

Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales

BMC Infectious Diseases
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader, John H. Kimbrough, Rodrigo E. Mendes, Mariana Castanheira   +3 more
doaj   +1 more source

Occurrence and spread of carbapenemase‐producing Enterobacterales (CPE) in the food chain in the EU/EFTA. Part 1: 2025 update

EFSA Journal, Volume 23, Issue 4, April 2025.
Abstract Carbapenemase‐producing Enterobacterales (CPE) have been reported in the food chain in 14 out of 30 EU/EFTA countries. Commonly reported genes are blaVIM‐1, blaOXA‐48 and blaOXA‐181, followed by blaNDM‐5 and blaIMI‐1. Escherichia coli, target of most of the studies, Enterobacter cloacae complex, Klebsiella pneumoniae complex and Salmonella ...
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Ana Allende, Avelino Álvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Lieve Herman, Liesbeth Jacxsens, Lapo Mughini‐Gras, Maarten Nauta, Jakob Ottoson, Fernando Pérez‐Rodríguez, Panagiotis Skandamis, Elisabetta Suffredini, Hector Argüello, Johan Bengtsson‐Palme, Alessandra Carattoli, Anke Kohlenberg, Dominique L. Monnet, Laurent Poirel, Beatriz Guerra, Raquel García‐Fierro, Ernesto Liébana, Sonagnon Martin Goudjihounde, Núria Ferrer‐Bustins, Hanne Rabbås, Luisa Peixe   +28 more
wiley   +1 more source

In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex

Antibiotics
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

BMC Pulmonary Medicine
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader, Rodrigo E. Mendes, S. J. Ryan Arends, Timothy B. Doyle, Mariana Castanheira   +4 more
doaj   +1 more source

Susceptibility to novel antimicrobial agents and molecular epidemiology of carbapenem-resistant enterobacterales: a 9-year study in Central China

BMC Microbiology
Purpose This nine-year (2016–2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on ...
Yungang Han, Qi Wang, Hao Chen, Zheng Li, Yali Wang, Yue Zhao, Shuang Xia, Wenyi He, Xiangjie Qiu, Huihui Chen, Jing Li, Yingying Yuan, Wei Wang   +12 more
doaj   +1 more source

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj   +1 more source

Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents

Frontiers in Microbiology
The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment ...
Emily Salisbury, Emily Salisbury, Kieran Mulroney, Kieran Mulroney, Malgorzata K. Kopczyk, Malgorzata K. Kopczyk, Teagan Paton, Teagan Paton, Christine F. Carson, Wai Shaun Ho, Wai Shaun Ho, Aron Chakera, Aron Chakera, Aron Chakera   +13 more
doaj   +1 more source

Spotlight commentary: Treatment of multidrug‐resistant Gram‐negative infections in the era of growing antimicrobial resistance

British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2485-2489, September 2025.
Luka Bielen, Andro Vujević, Luka Csenar
wiley   +1 more source

EVALUATION OF THE MINIMUM INHIBITORY CONCENTRATION OF MEROPENEM AND NEW THERAPEUTIC OPTIONS FOR SERRATIA MARCESCENS AND MORGANELLACEAE ENTEROBACTERALES WITH REDUCED SUSCEPTIBILITY TO MEROPENEM

Brazilian Journal of Infectious Diseases
Introduction/Objective: Serratia marcescens and Enterobacterales of the Morganellaceae family are associated with infections in different sites and exhibit an expected phenotype of resistance to several antimicrobials, making therapeutic options very ...
Lívia Medeiros, Eduarda Castro Oliveira, Mariana Preussler Mott, Bruno Watanabe, Rodrigo Minuto Paiva, Larissa Lutz   +5 more
doaj   +1 more source

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties

Transplant International
Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) and Pseudomonas aeruginosa are leading causes of morbidity and mortality after lung transplantation (LuTx).
Andrea Lombardi, Andrea Lombardi, Davide Mangioni, Giulia Viero, Laura Alagna, Giulia Renisi, Paola Saltini, Alessandra Bandera, Alessandra Bandera   +8 more
doaj   +1 more source